000724550 000__ 05389cam\a2200493Ii\4500
000724550 001__ 724550
000724550 005__ 20230306140538.0
000724550 006__ m\\\\\o\\d\\\\\\\\
000724550 007__ cr\cn\nnnunnun
000724550 008__ 141201s2015\\\\nyua\\\\o\\\\\001\0\eng\d
000724550 019__ $$a908088491
000724550 020__ $$a9781493921430$$qelectronic book
000724550 020__ $$a1493921436$$qelectronic book
000724550 020__ $$z9781493921423
000724550 035__ $$aSP(OCoLC)ocn897115858
000724550 035__ $$aSP(OCoLC)897115858$$z(OCoLC)908088491
000724550 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dYDXCP$$dOCLCO$$dGW5XE$$dOCLCF$$dN$T$$dIDEBK$$dEBLCP
000724550 049__ $$aISEA
000724550 050_4 $$aRC280.M37$$bB73 2015
000724550 08204 $$a616.99/477$$223
000724550 24500 $$aBRAF targets in melanoma$$h[electronic resource] :$$bbiological mechanisms, resistance, and drug discovery /$$cRyan J. Sullivan, editor.
000724550 264_1 $$aNew York :$$bHumana Press,$$c2015.
000724550 300__ $$a1 online resource (viii, 204 pages) :$$billustrations (some color).
000724550 336__ $$atext$$btxt$$2rdacontent
000724550 337__ $$acomputer$$bc$$2rdamedia
000724550 338__ $$aonline resource$$bcr$$2rdacarrier
000724550 4901_ $$aCancer drug discovery and development,$$x2196-9906 ;$$vvolume 82
000724550 500__ $$aIncludes index.
000724550 5050_ $$aContributors; Chapter-1; Melanoma: Historical Context; 1.1 Introduction; 1.2 Epidemiologic Trends; 1.3 Evolution in Surgical Management; 1.4 Adjuvant Therapy; 1.5 Evolution of Systemic Treatment Approaches; 1.6 Immunotherapy; 1.7 Conclusion; References; Chapter-2; Melanoma Pathogenesis; 2.1 Melanocyte Biology; 2.2 Melanoma Risk Factors; 2.3 MAPK and PI3K Pathways; 2.4 RB and p53 Pathways; 2.5 MITF; 2.6 Acral and Mucosal Melanomas; 2.7 Uveal Melanoma; 2.8 Melanoma Genomics; 2.9 Conclusion; References; Chapter-3; Molecular Diagnostics and Tumor Mutational Analysis; 3.1 Introduction
000724550 5058_ $$a3.2 Somatic Mutations in Melanoma3.2.1 UV Damage-Induced Mutations; 3.2.2 BRAF Mutations; 3.2.3 NRAS Mutations; 3.2.4 KIT Mutations; 3.3 Somatic Mutation Testing-Technology; 3.3.1 Direct Sequencing; 3.3.2 Genomic Aberrations; 3.3.3 Massively Parallel Sequencing; 3.3.4 Results of Whole Exome Sequencing/Whole Genome Sequencing in Melanoma; 3.4 Conclusion; References; Chapter-4; Clinical Utility of BRAF-Targeted Therapy in Melanoma; 4.1 Introduction; 4.2 BRAF Inhibitors; 4.2.1 Sorafenib; 4.2.2 Vemurafenib; 4.2.2.1 Early Phase Studies; 4.2.2.2 Phase II/III Studies and Subsequent Experience
000724550 5058_ $$a4.2.3 Dabrafenib4.2.3.1 Early Phase Trials; 4.2.3.2 Phase III Clinical Trial; 4.2.4 Encorafenib (LGX818); 4.2.5 Secondary Malignancies and Rare Toxicities; 4.2.6 Summary; 4.3 MEK Inhibitors; 4.3.1 Selumetinib; 4.3.2 Trametinib; 4.3.2.1 Early Phase Trials; 4.3.2.2 Phase III Trial; 4.3.2.3 Trametinib in BRAF Inhibitor-Resistance; 4.3.3 Binimetinib (MEK162); 4.3.4 Conclusions; 4.4 Combination Therapy; 4.4.1 Rationale and Efficacy; 4.4.2 Toxicity; 4.4.3 Crossover; 4.4.4 Current Status of Combination Therapies; 4.4.5 Summary; 4.5 Special Clinical Situations
000724550 5058_ $$a4.5.1 Targeted Therapy in Brain Metastases4.5.2 Treatment Beyond Progression; 4.5.3 Non-V600E Melanoma; 4.6 Conclusion and Future Directions; References; Chapter-5; The Ethics of Randomized Trials in Oncology; 5.1 Introduction; 5.2 A Brief History of Clinical Research in Humans: Selected Examples; 5.3 Ethical Guidelines for Clinical Research; 5.4 Clinical Trials: Research Questions and Study Design; 5.4.1 Advantages of Randomized Controlled Trials (RCTs); 5.4.2 Ethical Considerations in the Design of RCTs; 5.5 Ethical Issues in the Conduct of Clinical Trials
000724550 5058_ $$a5.6 Special Issues in Oncology Clinical Trials5.7 Case Study: Ethical Issues in the BRIM-3 Trial; References; Chapter-6; Parallel and Serial Blockade Strategiesin BRAF-Mutant Melanoma; 6.1 Introduction; 6.2 Molecular Biology of Melanoma; 6.3 Development of BRAF Inhibitors; 6.4 Rationale for Dual Inhibition of the MAPK Pathway; 6.5 The PI3K-AKT Pathway as Combinatorial Target; 6.6 Other Targets and Oncogenes; 6.7 Summary and Future Directions; References; Chapter-7; Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy; 7.1 Introduction; 7.2 Cell Cycle
000724550 506__ $$aAccess limited to authorized users.
000724550 520__ $$a​This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted c.
000724550 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed February 18, 2015).
000724550 650_0 $$aMelanoma$$xTreatment.
000724550 7001_ $$aSullivan, Ryan J.,$$eeditor.
000724550 77608 $$iPrint version:$$aSullivan, Ryan J.$$tBRAF Targets in Melanoma : Biological Mechanisms, Resistance, and Drug Discovery$$dNew York, NY : Springer New York,c2014$$z9781493921423
000724550 830_0 $$aCancer drug discovery and development ;$$vvolume 82.
000724550 852__ $$bebk
000724550 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-1-4939-2143-0$$zOnline Access$$91397441.1
000724550 909CO $$ooai:library.usi.edu:724550$$pGLOBAL_SET
000724550 980__ $$aEBOOK
000724550 980__ $$aBIB
000724550 982__ $$aEbook
000724550 983__ $$aOnline
000724550 994__ $$a92$$bISE